Loading stock…

Inspire Medical Systems, Inc. (INSP) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

Inspire Medical Systems, Inc.

INSPMarket cap $1.95BPrice $67.5

Country🇺🇸United States

SectorHealthcare

IndustryHealthcare Equipment

Makes an implantable device that treats sleep apnea by stimulating a nerve to keep airways open during sleep, no mask required. It's the only FDA-approved alternative to CPAP machines that millions can't tolerate wearing nightly.

In Bastion Portfolios?

52W Return-14%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+31%10

Revenue Forecast

Rev CAGR (1y)-6%1

Rev CAGR (3y)+1%2

Rev CAGR (5y)+4%4

Earnings Forecast

EPS Growth Y+1-27%2

EPS Growth Y+2+21%8

EPS Growth Y+3+37%9

Quality

Margins

EBIT Margin6%3

Net Income Margin15%7

Free Cash Flow Margin13%7

Debt

Net Debt/EBITDA-3.710

Efficiency

ROE18%7

ROA16%10

Earnings Stability22

GEAR+WEAK21

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)531

P/E Ratio (Forward 3y)321

P/BV2.46

EV Multiples

EV/EBITDA Fwd97

EV/EBIT Fwd411

Yield

Free Cash Flow Yield6.0%7

Dividend Yieldna–

Momentum

Short term

1 month return+9%10

3 month return+37%10

YTD return-27%2

Mid term

Price vs 52wHigh46%1

1 year return-14%3

Long term

3 year return-62%1

5 year return-71%1

Risk Shield

Price Risk

Beta0.94

Volatility70%1

Free Cash Flow

Free Cash Flow Margin13%7

Free Cash Flow Yield6.0%7

Quality

ROCE7%4

Earnings Stability22

Net Debt/EBITDA-3.710

02Growth

Is it actually growing, and how fast?

INSPInspire Medical Systems

Revenue FY25$803M

GROWTH RATING↗

WEAK26 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+31%10

Revenue, next 1Y-6%1

Revenue, next 3Y, CAGR+1%2

Revenue, next 5Y, CAGR+4%4

EARNINGS FORECAST▾SCORE

EPS growth, FY26E-27%2

EPS growth, FY27E+21%8

EPS growth, FY28E+37%9

GROWTH ASSESSMENT

STRENGTHS

Revenue grew 31%/yr over the last 3 years, ahead of 90% of companies worldwide.10/10

WATCH

Revenue grew 31%/yr over the last 3 years; forecasts see it cooling to 1%/yr.

Over five years revenue is set to grow 4%/yr, behind 60% of companies worldwide.4/10

Earnings are set to grow faster than sales (EPS about 21%/yr vs revenue 1%/yr), so margins should widen. One year dips: EPS falls 27% next year.

WEAKNESSES

Growth is the weak spot here, trailing 74% of companies worldwide.

Revenue is set to grow 1%/yr over the next 3 years, behind most of the market.2/10

BOTTOM LINE

Margin Expander

Growth is a weak point here: a business that is slowing. The one thing to watch: forward revenue growth trails the market.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

WEAK31 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+9%10

3-month return+37%10

YTD return-27%2

MID & LONG-TERM▾SCORE

% of 52-week high46%1

1-year return-14%3

3-year return-62%1

5-year return-71%1

MOMENTUM ASSESSMENT

STRENGTHS

Strong recent results. The stock is outperforming over the past month (+9%) and over three months (+37%).

WATCH

None flagged.

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (-62% over three years and -71% over five), behind 90% of the market.

It's down 14% over the past year, now 54% below its 52-week high. That is lagging the market.

The stock is underperforming so far this year (-27%).

BOTTOM LINE

Early Turnaround

A poor multi-year track record but a sharp recent rally. Momentum is turning up, yet the trend is young and unproven — it needs follow-through to confirm rather than fade. The one thing to watch: the multi-year record is weak.

04Value

Are you paying a fair price for it?

Stop guessing on Inspire Medical Systems, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

INSPInspire Medical Systems

Revenue FY25$803M

GROWTH RATING↗

WEAK26 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+31%10

Revenue, next 1Y-6%1

Revenue, next 3Y, CAGR+1%2

Revenue, next 5Y, CAGR+4%4

EARNINGS FORECAST▾SCORE

EPS growth, FY26E-27%2

EPS growth, FY27E+21%8

EPS growth, FY28E+37%9

GROWTH ASSESSMENT

STRENGTHS

Revenue grew 31%/yr over the last 3 years, ahead of 90% of companies worldwide.10/10

WATCH

Revenue grew 31%/yr over the last 3 years; forecasts see it cooling to 1%/yr.

Over five years revenue is set to grow 4%/yr, behind 60% of companies worldwide.4/10

Earnings are set to grow faster than sales (EPS about 21%/yr vs revenue 1%/yr), so margins should widen. One year dips: EPS falls 27% next year.

WEAKNESSES

Growth is the weak spot here, trailing 74% of companies worldwide.

Revenue is set to grow 1%/yr over the next 3 years, behind most of the market.2/10

BOTTOM LINE

Margin Expander

Growth is a weak point here: a business that is slowing. The one thing to watch: forward revenue growth trails the market.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

WEAK31 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+9%10

3-month return+37%10

YTD return-27%2

MID & LONG-TERM▾SCORE

% of 52-week high46%1

1-year return-14%3

3-year return-62%1

5-year return-71%1

MOMENTUM ASSESSMENT

STRENGTHS

Strong recent results. The stock is outperforming over the past month (+9%) and over three months (+37%).

WATCH

None flagged.

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (-62% over three years and -71% over five), behind 90% of the market.

It's down 14% over the past year, now 54% below its 52-week high. That is lagging the market.

The stock is underperforming so far this year (-27%).

BOTTOM LINE

Early Turnaround

04Value

Are you paying a fair price for it?

Stop guessing on Inspire Medical Systems, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community